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Abstract
Background & Aims—It is a challenge to develop direct-acting antiviral agents (DAAs) that
target the NS3/4A protease of hepatitis C virus (HCV) because resistant variants develop.
Ketoamide compounds, designed to mimic the natural protease substrate, have been developed as
inhibitors. However, clinical trials have revealed rapid selection of resistant mutants, most of
which are considered to be pre-existing variants.
Methods—We identified residues near the ketoamide-binding site in X-ray structures of the
genotype 1a protease, co-crystallized with boceprevir or a telaprevir-like ligand, and then
identified variants at these positions in 219 genotype 1 sequences from a public database. We used
side-chain modeling to assess the potential effects of these variants on the interaction between
ketoamide and the protease, and compared these results with the phenotypic effects on ketoamide
resistance, RNA replication capacity, and infectious virus yields in a cell culture model of
infection.
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Results—Thirteen natural binding-site variants with potential for ketoamide resistance were
identified at 10 residues in the protease, near the ketoamide binding site. Rotamer analysis of
amino acid side-chain conformations indicated that 2 variants (R155K and D168G) could affect
binding of telaprevir more than boceprevir. Measurements of antiviral susceptibility in cell culture
studies were consistent with this observation. Four variants (Q41H, I132V, R155K, and D168G)
caused low-to-moderate levels of ketoamide resistance; 3 of these were highly fit (Q41H, I132V,
and R155K).
Conclusions—Using a comprehensive sequence and structure-based analysis, we showed how
natural variation in the HCV protease NS3/4A sequences might affect susceptibility to first-
generation DAAs. These findings increase our understanding of the molecular basis of ketoamide
resistance among naturally existing viral variants.
Keywords
virology; genetic; drug resistance; treatment
Until recently, the standard of care (SOC) for patients with chronic hepatitis C virus (HCV)
infection has consisted of a combination of pegylated interferon-α plus ribavirin (Peg-IFN/
RBV), administered for 24- to 48-weeks depending on the HCV genotype1–3. The sustained
virologic response (SVR) rate for this SOC has been only about 50% in patients infected
with genotype 1 HCV, the most prevalent genotype in Europe and North America. The
addition of a direct-acting antiviral agent (DAA) targeting the NS3/4A serine protease of
HCV significantly improves the SVR rate, and two such drugs have recently been approved
for clinical use in the United States. The ketoamide compounds boceprevir (SCH503034)
and telaprevir (VX-950) were both designed to mimic the natural substrate of the
protease4–6. Clinical trials in treatment-naïve genotype 1-infected patients have revealed
significant improvements in the kinetic of the virologic response with the addition of a DAA
to the prior SOC, leading to improved SVR rates of up to 74%7–9.
Unlike Peg-IFN/RBV, the selection of drug-resistant virus variants during treatment with
protease inhibitors (PIs) is a major concern. According to recent calculations by Rong et
al.10, most, if not all, potential drug-resistant viral variants pre-exist at low frequencies
within the viral quasispecies population in untreated patients. The highly replicative nature
of HCV infection, with approximately 1012 new virions produced each day in the typical
infected individual11, coupled with the lack of proofreading activity in the RNA-dependent
RNA polymerase, NS5B, results in the generation of every possible viral variant every day.
Thus, each patient is infected with a viral quasispecies “cloud” comprised of genetically
distinct but closely related viral genomes. In the absence of concomitant Peg-IFN/RBV
therapy, drug-resistant viral variants are rapidly selected and may emerge at frequencies as
high as 5–20% in the quasispecies of patients as early as the second day of treatment. Unless
suppressed by concomitant PegIFN/RBV, these pre-existing resistant variants are likely to
be selected with subsequent treatment failure10.
The NS3/4A protease plays an essential role in the HCV replication cycle by proteolytically
processing non-structural proteins from the viral polyprotein downstream of the NS2–3
junction12. The protease domain of NS3, comprising the amino-terminal third of the protein
contains a catalytic triad, H57, D81 and S139, and an “oxyanion hole” at G137. It acts in
concert with its cofactor, NS4A, which intercalates into its structure and is required for full
enzymatic activity and proper subcellular localization. The carboxy-terminal two-thirds of
NS3 comprises a DExD-box RNA helicase domain that is essential for productive viral
infection13. NS3 thus appears to be a critical component of the macromolecular viral RNA
replicase that directs the synthesis of new viral RNAs. Genetic evidence indicates that NS3
has an additional distinct function in assembly of virus particles14, 15. Since viral RNA
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replication capacity and virus assembly are crucial determinants of viral fitness, mutations in
NS3 that contribute to PI resistance can also profoundly influence virus fitness16. The
probability of a resistant variant emerging from the quasispecies population during treatment
with a DAA is determined not only by its degree of resistance, but also by its fitness. Many
mutations associated with PI resistance negatively impact the replication of genotype 1a
HCV RNA in cell culture, while some have additional effects on the production of infectious
virus14. Compensatory second-site mutations may enhance the fitness of resistant viruses16,
but current understanding of these is rudimentary.
Given the genetic diversity that exists among different HCV strains, it is possible that
naturally occurring polymorphisms in the NS3/4A sequence could provide a priori resistance
to DAAs, and thus negatively impact the success of future treatment regimens. Here, we
have studied the variation in amino acid residues that neighbor ketoamide compounds in the
ligand-binding site of the protease. We identified natural amino acid substitutions at these
positions in NS3 among genotype 1a sequences deposited in a public database, and modeled
their side-chain conformations to assess their potential impact on ketoamide binding. To
corroborate these in silico predictions, we then introduced these amino acid substitutions
into a cell culture-infectious genotype 1a virus (H77S.3)14 and determined their impact on
both susceptibility to ketoamide PIs and replication fitness in a cell culture system.
MATERIALS AND METHODS
Details of the materials and methods can be found in the Supplementary Material.
In silico analysis
We used X-ray structures of the genotype 1a HCV NS3/4A protease from the Protein
Databank RCSB PDB17 co-crystallized with boceprevir (PDB 2OC8) or a telaprevir-like
ligand (TLL, PDB 2P59) to deduce sets of ketoamide-neighboring residues. We designated
the P4 to P1 and P1’ groups for ligands and their corresponding specificity pockets within the
ligand-binding site, S4 to S1 and S1’, according to the numbering scheme of Schechter and
Berger18. We then analyzed 219 genotype 1a HCV NS3/4A sequences deposited in the
European HCV database19, which contains sequences collected from around the world, to
identify potential natural binding site variants (BSVs) at residues that neighbor the
ketoamides within the structure of the protease. The side-chain conformations of these BSVs
were modeled using IRECS20 (details in Supplementary Material).
Cell culture and reagents
Details of the cells and reagents used in this study are provided in Supplementary Material.
Plasmids
pH77S.3 and pH77S.3/GLuc2A are molecular clones of the genotype 1a H77 strain of HCV.
Synthetic RNA transcribed from these plasmids replicates in transfected Huh7 cells and
produces infectious virus14. pH77S.3/GLuc2A RNA also produces secreted Gaussia
luciferase (GLuc) reporter protein. Amino acid substitutions in BSVs expected to impact
ketoamide binding were created in these plasmids by site-directed mutagenesis14.
Virus fitness and antiviral resistance
Genome-length RNA was transcribed from the mutated pH77S.3 and pH77S.3/GLuc2A
plasmids in vitro, and studies to assess antiviral resistance and viral fitness carried out as
described previously14.
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RESULTS
To identify amino acid residues in NS3 that are in close proximity to ketomides in the
ligand-binding site of the protease, we analyzed PDB structure 2OC8 in which boceprevir is
co-crystallized with the NS3/4A protease21. Since no similar co-crystallized structure is
publically available for telaprevir, we used PDB structure 2P59 in which the protease is co-
crystallized with a telaprevir-like ligand (TLL) that has two small differences from
telaprevir22. Its P2 group and the P4 capping group are slightly modified, with the P4
providing a pyrrole NH for H-bond interactions with the protease (Supplementary Fig.
S1)23. We identified 20 residues interacting with or neighboring boceprevir and TLL in
these X-ray structures (Table 1 and Supplementary Materials and Methods), and analyzed
genotype 1a HCV sequences in the European HCV database to identify differences from the
consensus sequence at these residues. The residues were relatively well conserved in 219
genotype 1a sequences from diverse geographic regions. However, we identified 13
different binding site variants (BSVs) involving 10 ketoamide-neighboring residues
(Supplementary Table S1 and Fig. S2), 8 of which have not been described previously as PI
resistance-associated variants. None of the patients from which these sequences were
derived appear to have been treated previously with a DAA (see Supplementary Table S3).
Most of these naturally occurring BSVs were single amino acid substitutions without
changes in other ketoamide-neighboring residues. However, T42A and K136R were both
present within a single sequence (EU677251). Two different BSVs were identified as
substitutions at T42 (A/S), V55 (A/I) and D168 (G/E), while single BSVs were identified at
the other 7 residues (Supplementary Table S1 and Fig. S2). We examined the first-neighbor
residues of these BSVs in an effort to identify potential second-site variants in the BSV
strains (see Supplementary Material and Methods, Fig. S3 and Table S2). While there were
no additional substitutions at these first-neighbor residues in most BSVs, T54S was found in
both V55I strains (EF407443 and EU781818) and I170V was found in a R155K strain
(EU781805).
Rotamer analysis of BSVs and expected impact on ketoamide binding
We modeled the energetically most favorable side-chain conformations for the genotype 1a
consensus and BSV sequences (Fig. 1). Since V55 is buried in the protease domain24, it was
not amenable to rotamer analysis. Molecular dynamics simulation of variants at this position
will be reported separately (Welsch et al., in revision).
Expected impact of Q41H and K136R at the ketoamide P1’ position—Q41 is
located adjacent to S1’. The H41 variant represents a non-conservative change from the
consensus sequence involving substitution of an uncharged polar side chain with a charged
aromatic residue. Telaprevir possesses a cyclopropyl group at P1’ that is oriented away from
the Q41 side chain without noncovalent interactions. The conformation of Q41 suggests a
potential H-bond interaction of its carboxamide chain, including the H-bond donor NH2 and
acceptor C=O, with the backbone of boceprevir and TLL (OE1—HN distance for Q41-
ketoamide: 2.7 Å). However, the H41 BSV has no side-chain group allowing an H-bond
interaction with the ligand (Fig. 2A). This suggests H41 will be associated with a minor
decrease in binding affinity for boceprevir and telaprevir.
In contrast, K136R is a conservative change between polar residues, both with long, flexible
and charged side chains at S1’. The K136 side chain is not defined in the electron density
map of PDB structure 2P59. As modeled, it has close contacts with the TLL P1’ cyclopropyl
group (Fig. 2B). Boceprevir possesses no comparable P1’ group (Supplementary Fig. S1).
We predict the R136 side-chain conformation is similar to the wild-type K136, but that it
will wrap around the TLL cyclopropyl group providing an increasing number of van der
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Waals contacts (Fig. 2B). This suggests that the R136 variant may have stronger effects on
telaprevir than on boceprevir binding. We expect hydrophilicity to play a role in ketoamide
binding at S1’, and the R136 side chain possesses more polar contacts and potentially binds
more water molecules than the wild-type K136. Thus, the release of water molecules bound
to the R136 side chain could increase systemic entropy and potentially add to the free
binding energy and affinity for telaprevir, although decreased enthalpy may compensate for
the effects on entropy. Since the R136 side chain does not have a tight H-bond or salt bridge
interaction at its end, electrostatic attraction between the nonpolar P1’ cyclopropyl group of
telaprevir and the polar R136 side chain is unlikely. Overall, however, the impact of K136R
on binding of telaprevir is not readily predicted by rotamer analysis alone.
Expected impact of I132V and F154Y on ketoamide P1 and P3 interactions—
I132 is located adjacent to S1 and S3, and its substitution with valine in V132 represents a
conservative change between hydrophobic residues. The consensus I132 side-chain
conformation forms a hydrophobic S1/3 interface with the ketoamide P1 and P3 groups. The
I132 side-chain Cδ carbon points towards the ketoamide P3 group (Fig. 3A). The variant
V132 shows a similar side-chain conformation but without a Cδ carbon. This suggests a loss
of van der Waals contacts for V132, resulting in a minor reduction in binding affinity for
boceprevir and telaprevir. F154Y is also a relatively conservative change, in this case from
nonpolar towards polar among aromatic residues. This residue is close to the ketoamide P1
and P3 groups at the bottom of the S1 pocket. The wild-type F154 and the predicted variant
Y154 side chains are oriented towards the ketoamide P1 group, potentially influencing
boceprevir and telaprevir binding (Fig. 3B). The Y154 side-chain has an OH group that is
not present in the wild-type F154. Ketoamides do not offer an opportunity for H-bond
interactions at P1, but this OH group may provide for alternative binding of a water
molecule. The polar, hydrophilic nature of the Y154 side chain reduces the hydrophobic
properties of the S1 pocket, and this variant is expected to cause a significant reduction in
binding affinity for boceprevir and telaprevir.
Expected impact of R155K, D168E and D168G on ketoamide P2 and P4
interactions—R155K is a conservative change between positively-charged residues within
the S2 pocket The R155 side chain is predicted to participate in a pattern of noncovalent
interactions involving its neighboring residues, R123 and D168, at S4 (the O-H distance for
D168-R155 is 2.6 Å; for R123-D168, it is 2.5 Å) (Fig. 4). The combination of H-bond and
electrostatic interactions is predicted to result in a particularly strong noncovalent salt
‘bridge’ interaction. Polar interactions between the D168, R123 and R155 side chains
contribute to the strength of this noncovalent interaction network. The D168 side chain is
predicted to be tightly fixed, allowing no other H-bond interaction and contributing to a
nonpolar S2/4 interaction interface for the P2 and P4 groups in boceprevir and telaprevir. The
variant K155 disrupts this nonpolar S2/4 interface by leaving the negatively-charged D168
unbound, and is expected to reduce binding affinity for boceprevir and telaprevir. A stronger
effect is expected for telaprevir than for boceprevir, since the telaprevir P2 cyclopental-
proline is larger than the respective boceprevir isopropyl-proline (Supplementary Fig. S1).
Compared with R155, the K155 side-chain is also predicted to be shifted slightly away from
the ketoamide P2 group. This shift is likely to cause a loss in van der Waals contacts with the
ketoamide P2 group, and may reduce binding affinity for telaprevir. The effects on polarity
and loss of van der Waals contacts suggest that there will be a significant decrease in
binding affinity for both ketoamides, but a larger impact on telaprevir.
Two variants were observed at the D168 position that contributes to the S4 pocket in the
protease. D168G is a non-conservative change from aliphatic and polar to a smaller,
nonpolar side chain. The wild-type D168 side-chain conformation is oriented towards the
ketoamide P4 group, which is smaller in boceprevir than telaprevir. The extended P4 group
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in telaprevir (Fig. 1) points away from D168. Thus, the D168 variant is expected to have
only minor effects on ketoamide binding. G168 is expected to have effects on the nonpolar
S2/4 interface similar to K155, since it offers no polar side-chain interaction partner for
R155. It is predicted to change the polarity of the S2/4 interface and expected to cause a
minor decrease in binding affinity for both ketoamides. D168E is a conservative change as
both side-chains are negatively charged and aliphatic. The side-chain conformation is
predicted to be similar to the wild-type D168, and to preserve S2/4 interface polarity. D168E
is not expected to impact ketoamide binding.
Additional BSVs without expected impact on ketoamide binding—T42A is
located at the periphery of the S1’ pocket, and is a non-conservative change from aliphatic,
polar and negative towards aliphatic and hydrophobic. A side-chain OH group is lost in the
A42 variant, but preserved in the S42 variant at this position, allowing for a potential H-
bond interaction. The wild-type T42 and variant A42 and S42 side-chain conformations are
predicted to be similar. No ketoamide H-bond donor or acceptor group is found in close
proximity to T42 or S42. Due to its relative distance from the ketoamide, the polarity change
in T42A is predicted not to have a significant effect on ketoamide binding. Thus, the T42A/
S variants are expected to have no impact on ketoamide binding. F43S is a non-conservative
change from aromatic and nonpolar towards aliphatic and polar, and is found at the bottom
of S1’. No change is predicted in the side-chain conformation. There is an additional OH
group in the variant, but since there is no ketoamide H-bond donor or acceptor group in
close proximity, this by itself is unlikely to have any impact on ketoamide binding.
Nevertheless, F43S may cause ketoamide resistance since the F43 aromatic ring directly
participates in the formation of the S1’ pocket, which impacts binding of the ketoamide P1’
group25. Substitutions at F43 have been shown previously to cause resistance to ketoamide
compounds25. T160A is a non-conservative change from polar towards nonpolar and
hydrophobic, located at a distance from S4 near the boundary of an extended S5 pocket.
T160 interacts directly with the extended P4 group in TLL in the PDB structure 2P59, but
has no noncovalent interactions with boceprevir in PDB structure 2OC8. The variant A160
side-chain is not expected to influence ketoamide binding.
Replication capacity and infectious virus yield from RNAs containing BSVs
Those BSVs for which the rotamer analysis suggested a possible impact on ketoamide
binding (Q41H, I132V, F154Y, R155K and D168G) were selected for phenotypic
characterization. We similarly tested K136R, for which the rotamer analysis provided no
clear predictions. The amino acid substitutions were created within the background of the
genotype 1a H77S.3 genome, and their impact on replication of the viral RNA and
production of infectious virus determined in RNA-transfected cells.
(1) RNA replication capacity—The replication capacity of H77S.3/GLuc2A RNA
mutants with BSV substitutions in NS3 was assessed by measuring GLuc activities in
supernatant media collected at 24h intervals following transfection of synthetic RNA, as
described previously14. Results were normalized to the activity present at 6h after
transfection, as this represents GLuc expressed directly by the transfected input RNA. The
RNA replication capacity of the Q41H variant was similar to the parental H77S.3/GLuc2A
RNA, while I132V and K136R were minimally impaired (Fig. 5A). In contrast, as shown
previously14, the replication of R155K was moderately impaired while D168G was severely
handicapped for RNA replication. The maximum RNA replication capacity observed was
with Q41H (89% of parental RNA) while the lowest was with D168G (5.5%). The F154Y
substitution had a lethal effect on RNA replication in the H77S.3 background, suggesting
that viruses containing this sequence variant (and possibly also G168) possess one or more
compensating changes at other amino acid positions (see Discussion). None of the BSVs
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demonstrated enhanced RNA replication capacity compared to the parental H77S.3/GLuc2A
RNA (Fig. 5B).
(2) Infectious virus yield—We also assessed the impact of these BSVs when placed
within the background of H77S.3 RNA, which lacks the GLuc2A-coding sequence and
produces infectious virus as described previously14. Cell culture supernatant fluids were
collected 72h after transfection of the RNA, and subsequently inoculated onto naïve cells,
with foci of infected cells detected by immunofluorescence 72h later. Each of the BSVs
tested produced infectious virus yields in the range of that expected from their RNA
replication capacity, although the low replication capacity of the D168G variant precluded a
careful analysis on production of infectious virus (Fig. 5). Thus, none of these amino acid
substitutions were documented to directly impair infectious virus assembly or release, as
described previously for some resistance-associated NS3 variants14. Reductions in the
fitness of these particular BSVs are confined primarily to defects in viral RNA replication.
Ketoamide resistance of BSVs
We measured the antiviral activities (EC50) of boceprevir and telaprevir against each of the
H77S.3/GLuc2A mutants by determining the concentration of each compound required to
cause a 50% reduction in RNA replication (GLuc expression by RNA-transfected cells).
Resistance testing could not be performed for the F154Y variant because it was not
competent for replication.
Boceprevir demonstrated antiviral activity against each of the BSVs (Table 2). The EC50
value against the parental H77S.3/GLuc2A was 870 ± 48 nM. The maximum fold-change in
the EC50 for any of the BSVs was 2.1 for R155K14. Only R155K showed significant, albeit
low-level resistance against boceprevir. Telaprevir showed greater molar activity than
boceprevir, with an EC50 against the H77S.3/GLuc2A of 120 ± 10 nM. As with boceprevir,
telaprevir was active against each of the BSVs, but low- to medium-level resistance was
evident with Q41H, I132V, R155K and D168G (Table 2). The maximum fold-change in the
EC50 was 8.8 for R155K. As expected from the in silico analysis, the range of fold-changes
in EC50 was broader for telaprevir than boceprevir. In general, these changes were in good
agreement with the impact of these BSVs on ketoamide binding predicted from the rotomer
analysis, except for K136R which was difficult to predict and showed greater antiviral
activity than anticipated against both ketoamide compounds (Table 2).
DISCUSSION
Mathematical arguments suggest that every possible drug-resistant viral variant is likely to
pre-exist at a low frequency in the replicating viral quasispecies population of the typical
HCV-infected patient10. Whether this is actually the case, and at what frequency such
variants actually exist, may never be formally demonstrated due to technical difficulties. In
this study, we analyzed the natural variation present among ketoamide-neighboring residues
in 219 genotype 1a HCV sequences collected from geographically diverse sites and
deposited in a public database. We cannot exclude the possibility that some of the BSVs we
identified in this set of sequences may represent variants that were present at low frequency
in their source patient, or even unrecognized sequencing errors. However, it is likely that
they represent true variants present within the dominant quasispecies of the patients from
which these sequences were derived, since multiple BSVs were identified at some residues
(T42, V55, and D168) (Supplementary Fig. S2), while others (H41, A42, A55, I44, and
K155) were present in more than one sequence. We identified BSVs at one or more
ketoamide-neighboring residues in 17 of 219 (7.8%) genotype 1a sequences. Importantly, 8
of these variants (Q41H, T42A, T42S, V55I, I132V, K136R, F154Y, and T160A) have not
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been identified, to our knowledge, in previous in vivo or in vitro studies of ketoamide
resistance.
Although they are both linear ketoamide compounds, boceprevir and telaprevir have distinct
structural features (Supplementary Fig. S1). Telaprevir possesses an extended P4 capping
group and a P1’ cyclopropyl group. The P2 group is different from the isopropyl-proline in
boceprevir, which is smaller than the telaprevir P2 cyclopental-proline23. These structural
differences likely contribute to the lower EC50 of telaprevir against genotype 1a HCV in cell
culture (Table 2), but could also pose a higher risk for telaprevir resistance among BSVs.
Rotamer analysis predicted that two BSVs (R155K and D168G) would exert a greater
negative effect on the binding of telaprevir than boceprevir. The impact of the K136R
substitution proved difficult to predict on the basis of rotamer analysis alone, however, and
subsequent tests in cell culture demonstrated that it imposes no resistance against either
ketoamide (Table 2).
On the other hand, the R155K and D168G substitutions led to a 2- to 4-fold greater increase
in the EC50 of teleprevir compared with boceprevir, and almost a 9-fold increase in the
teleprevir EC50. This was consistent with predictions from the rotamer analysis, which also
agreed with previous crystallographic studies26. Whether such changes in the EC50 result in
clinical resistance would be dependent upon the potency of a drug and the drug exposure
achieved in a typical patient. A 2-fold change might not be clinically relevant, but a 9-fold
increase such as that found with R155K is likely to be significant. Importantly, R155K has
been associated previously with resistance to both ketoamide and macrocyclic
compounds23, 26.
Three BSVs (Q41H, I132V and F154Y) were predicted to interact with ketoamide structural
features common to both telaprevir and boceprevir, and thus to influence the binding of
these compounds equally. Although Q41H was expected to cause only a minor decrease in
affinity for both ketoamides, in vitro assays revealed a 3.5-fold increase in the EC50 for
teleprevir versus 1.2 for boceprevir. Its greater impact on telaprevir potency is likely related
to its P1’ cyclopropyl group and induced structural changes in the corresponding S1’ pocket.
Such changes were not detectable using rotamer analysis, but nonetheless probably
influenced the binding of telaprevir. A similar difference in the magnitude of the change in
EC50 was observed for the I132V variant (1.1 fold-change for boceprevir versus 2.4 for
teleprevir). This could result from a loss of van der Waals contacts with the ketoamide P3
group, which differs slightly in its orientation in the co-crystallized boceprevir and
TLLstructures (see Fig. 1). The F154Y substitution was lethal for RNA replication when
placed in the background of the H77S.3 virus, and thus we could not measure antiviral
activity against it.
Viral fitness coupled with the degree of resistance conferred by a BSV are likely to be the
major determinants driving selection of a variant from within the viral quasispecies during
therapy. RNA replication capacity is one measure of the fitness of the virus, and this is
dependent on proper processing of the polyprotein by NS3/4A. Ketoamides mimic the
natural substrate of the protease at the site of NS3-NS4A scission, and it is likely that the
negative influence of BSVs on RNA replication (Fig. 5A) reflects altered recognition of the
polyprotein substrate related to structural changes similar to those leading to drug resistance.
Despite this, there is no strong correlation between the degree of PI resistance and the
impact on RNA replication14. This is reflected in the marked deficit in replication
demonstrated by the D168G substitution (Fig. 1A), which confers only a minimal increase in
the teleprevir EC50 (Table 2). There is no obvious structural or molecular explanation for
this difference, and it is not possible to exclude the possibility that G168 might provide for
more robust RNA replication when placed in the context of a different virus sequence.
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In contrast F154Y was lethal for replication in the context of the H77S.3 virus. This
substitution occurs at a central position within the ligand-binding site at the bottom of the S1
pocket. A recent crystallographic study found the F154 aromatic ring to directly contact the
substrate P1 side-chain27. Thus, the complete loss of RNA replication observed with F154Y
could be due to either intrusion of the Y154 side-chain into the space normally occupied by
the polyprotein substrate, or a polarity shift within S1 due to the Y154 OH group.
Nonetheless, the presence of Y154 in the database suggests that it is capable of functioning
in an alternative sequence context. This highlights a limitation of the technical approach we
have taken here to study the phenotypic effect of BSVs, as second-site substitutions in the
same strain might compensate for defects fitness. In fact, the sequence of the F154Y BSV
(EU677253) contains two additional substitutions in NS3 that differ from the genotype 1a
consensus: R11G and H110R (Supplementary Fig. S2). H110R is in close structural
proximity to F154Y and the natural substrate of the protease (Supplementary Fig. S3). While
it might be preferable in investigating BSVs to engineer swaps of the complete NS3
sequence into the background of a replication-competent clone, it is not clear how often this
approach would fail due to sequence incompatibilities between the “donor” and “recipient”
viruses. NS3 appears to interact with several other viral proteins28.
Our findings provide a molecular basis for ketoamide resistance among BSVs that exist
naturally as dominant quasispecies in some patients prior to treatment with DAAs
(Supplementary Table S3). Such natural variants may be of limited clinical significance at
present as they are likely to be suppressed by Peg-IFN/RBV in current SOC regimens, but
they can be expected to be of substantial importance to the outcome of future interferon-
sparing, all-DAA combination therapies. These variants might also affect future generations
of inhibitors depending upon their chemical structures. Knowledge on the natural variability
in structures targeted by antivirals, as presented in this study, may help guide the
development of future generation PIs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ligand-binding site of NS3/4A with ketoamides and BSVs
(A) Surface representation from PDB structure 2OC8 with boceprevir shown in magenta.
Side-chains at amino acid residues with BSVs are shown in stick format (light blue). (B)
Similar representation of TLL within the PDB structure 2P59 with side-chains at amino acid
residues with BSVs (dark blue). (C) Superposition of boceprevir and TLL.
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Figure 2. Rotamer analysis of Q41H and K136R
Detail of PDB structure 2OC8 showing boceprevir (magenta) and the superposed TLL
(yellow). The panels on the left show the side-chain conformation of the consensus residue,
while those on the right show the predicted BSV conformation. (A) (left) The Q41 side-
chain OH-group with predicted H-bond interaction (dotted line) with ketoamide backbone
Cα, (right) this H-bond interaction is absent in H41. (B) Predicted R136 side-chain
conformation and the TLL P1’ cyclopropyl showing closer van der Waals contacts in (right)
R136 than in (left) the consensus K136.
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Figure 3. Rotamer analysis of I132V and F154T
(A) (left) The I132 side chain provides a hydrophobic S1/3 interface for the ketoamide P1
and P3 moieties. The I132 Cδ carbon is oriented towards the ketoamide P3, while (right)
V132 lacks a Cδ carbon. (B) (left) F154 neighbors S1 underneath the ketoamide, while
(right) Y154 is predicted to assume a similar side-chain conformation but with an additional
OH-group.
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Figure 4. Rotamer analysis of R155K
(left) The H-bond pattern (dotted lines) in the R155 structure with D168 serving as a
nonpolar S4 contact interface for the ketoamide P4. (right) K155 disables this H-bond
pattern, leaving D168 unbound with a polar OH-group at S4. The K155 side-chain
conformation is also predicted to be shifted slightly away from the ketoamide P2.
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Figure 5. Replication capacity and infectious virus yield of H77S.3 RNAs with BSV substitutions
in NS3
(A) RNA replication capacity reflected of H77S.3/GLuc2A BSV into Huh7.5 cells. Results
are normalized to the 6h GLuc activity, and represent the mean of triplicate samples. (B)
Comparison of RNA replication capacity (lightly shaded bars) and infectious virus yields
(dark shaded bars). Both are normalized to those obtained with the relevant parental RNA
(100%). Data represent the mean ± SD from at least 3 independent experiments
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Table 1
Ketoamide-neighboring residues in NS31.
Boceprevir Telaprevir-like ligand (TLL)
RCSB PDB UniProtKB RCSB PDB UniProtKB
2OC8 (Chain B) P27958 2P59 (Chain B) P27958
Q41 Q41 Q1067 Q41
T42 T422 T1068 T42
F43 F43 F1069 F43
V55 V55 - -
H57 H57 H1083 H57
D81 D81 D1107 D81
R123 R123 R1149 R123
I132 I132 I1158 I132
L135 L135 L1161 L135
K136 K136 K1162 K136
G137 G137 G1163 G137
S138 S138 S1164 S138
S139 S139 S1165 S139
F154 F154 F1180 F154
R155 R155 R1181 R155
A156 A156 A1182 A156
A157 A157 A1183 A157
V158 V158 V1184 V158
C159 C159 C1185 C159
- - T1186 T160
D168 D168 D1194 D168
1
Residues are numbered relative to the PDB residue sequence and H77c reference sequences (UniProtKB P27958).
2
Residues shown in italics do not directly interact with boceprevir or TLL, but are within 5.0 Å distance of the ligand (see Supplementary
Materials and Methods).
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